Clinical Trial

Terazosin and Parkinson's Disease Extension Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 2, 2026 (before its estimated March 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-10-26; most recent amendment 2026-02-26.
Status change: Recruiting → Active, Not Recruiting 2026-02-26
Status change: Not Yet Recruiting → Recruiting 2022-08-16
Trial Details
NCT Number NCT05109364
Lead Sponsor Cedars-Sinai Medical Center
Conditions Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Enrollment 15 participants
Start Date 2022-09-23
Primary Completion 2026-03-10 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-02